Marked-Up Copy
Serial No: 09/807,962
Amendment Filed: HEREWITH

IN THE CLAIMS

--1. (Amended) A method for treating cell proliferative disorders associated with an altered cell dependant kinase activity comprising administering to a subject in need thereof an effective amount thereof [The use] of a compound which is a 2-amino-1,3-thiazole derivative of formula (I)



(I)

wherein

R is isopropyl [a halogen atom, a nitro group, an optionally substituted amino group or it is a group, optionally further substituted, selected from:

i) straight or branched C_1-C_8 alkyl, C_2-C_6 alkenyl or C_2-C_6 alkenyl;

ii) C_3-C_6 cycloalkyl;

iii) aryl or arylalkyl with from 1 to 8 carbon atoms within the straight or branched alkyl chain] isopropyl;

R_1 is an optionally further substituted group selected from

i) straight or branched C_1-C_8 alkyl or C_2-C_6 alkenyl;

ii) 3 to 6 membered carbocycle or 5 to 7 membered heterocycle ring;

iii) aryl or arylcarbonyl;

iv) arylalkyl with from 1 to 8 carbon atoms within the straight or branched alkyl chain;

v) arylalkenyl with from 2 to 6 carbon atoms within the straight or branched alkenyl chain;

vi) an optionally protected amino acid residue;

or a pharmaceutically acceptable salt thereof[; in the manufacture of a medicament for treating cell proliferative disorders associated with an altered cell dependent kinase activity].

2. (Amended) [Use] The method according to claim 1 wherein the said cell proliferative disorder is selected from the group consisting of cancer, Alzheimer's disease, viral infections, auto-immune diseases or neurodegenerative disorders.

3. (Amended) [Use] The method according to claim 2 wherein the cancer is selected from the group consisting of carcinoma, squamous cell carcinoma, hematopoietic tumors of myeloid or lymphoid lineage, tumors of mesenchymal origin, tumors of the central and peripheral nervous system, melanoma, seminoma, teratocarcinoma, osteosarcoma, xenoderoma pigmentosum, keratoctanthoma, thyroid follicular cancer and Kaposi's sarcoma.

4. (Amended) [Use] The method according to claim 1 wherein the cell proliferative disorder is selected from the group consisting of benign prostate hyperplasia, familial adenomatosis polyposis, neuro-fibromatosis, psoriasis, vascular smooth cell proliferation associated with atherosclerosis, pulmonary fibrosis, arthritis glomerulonephritis and post-surgical stenosis and restenosis.

5. (Amended) [Use according to any one of the preceding claims] The method according to claim 1 wherein the [medicament] compound enables tumor angiogenesis and metastasis inhibition.

6. (Amended) A compound which is a 2-amino-1,3-thiazole derivative of formula (I)



(I)

wherein

R is <u>isopropyl</u> [a halogen atom, a nitro group, an optionally substituted amino group or it is a group, optionally further substituted, selected from:

i) straight or branched C_1-C_8 alkyl, C_2-C_6 alkenyl or C_2-C_6 alkynyl;

ii) C_3-C_6 cycloalkyl;

iii) aryl or arylalkyl with from 1 to 8 carbon atoms within the straight or branched alkyl chain];

R_1 is an optionally further substituted group selected from:

i) straight or branched C_1-C_8 alkyl or C_2-C_6 alkenyl;

ii) 3 to 6 membered carbocycle or 5 to 7 membered heterocycle ring;

iii) aryl or arylcarbonyl;

iv) arylalkyl with from 1 to 8 carbon atoms within the straight or branched alkyl chain;

v) arylalkenyl with from 2 to 6 carbon atoms within the straight or branched alkenyl chain;

vi) an optionally protected amino acid residue;

or a pharmaceutically acceptable salt thereof[; for use as a medicament; provided that each of R and R_1, independently, is not a methyl group and that the compound is not 2-diethylaminomethyl-carbonylamino-5-chloro-1,3-thiazole].

7. (Cancelled)

8. (Amended) A compound of formula (I), according to claim [7] <u>6</u>, wherein [R is a halogen atom or an optionally substituted group selected from a straight or branched C_1-C_4

alkyl, C_3-C_6 cycloalkyl, aryl or an arylalkyl with from 1 to 4 carbon atoms within the alkyl chain;] R_1 is an optionally substituted group selected from straight or branched C_1-C_4 alkyl or alkenyl, aryl or arylalkyl with from 1 to 4 carbon atoms within the alkyl chain or it is an optionally protected amino acid residue.

9.-11. (Cancelled)

12. (Amended) A process for producing a compound of formula (I), as defined in claim [7] 6 which process comprises reacting a compound of formula (II)



(II)

with a compound of formula (III)

$$R_1\text{–COX} \qquad \text{(III)}$$

wherein R and R_1 are as defined in claim [7] 6 and X is hydroxy or a suitable leaving group; and, if desired, converting a 2-amino-1,3-thiazole derivative of formula (I) into another such derivative of formula (I), and/or into a sa't thereof.

15-22 (New)--